论文部分内容阅读
子痫前期是妊娠期特发性多系统疾病,无论是在发达国家还是发展中国家,均为孕妇及围产儿死亡的主要原因之一[1-2]。在世界范围内,子痫前期的发生率约为5%~8%,发展中国家可高达15%~18%,每年约有75 000孕妇及500 000胎儿死于子痫前期的并发症[3],且子痫前期患者及其子代今后发生心血管疾病的风险均增加[4]。如何降低子痫前期的发生率,有效治疗子痫前期及其并发症,是当今广大妇产科医生努力研究的目标。但目前对于子痫前期的发生机制仍未完全明确,一氧化氮(nitric oxide,NO)/环鸟苷酸(cyclic guanosinc monophosphate,c GMP)通道被认为是影响
Pre-eclampsia is an idiopathic polygenic disease during pregnancy, which is one of the major causes of maternal and perinatal deaths in both developed and developing countries [1-2]. Worldwide, the prevalence of preeclampsia is about 5% to 8% and in developing countries it can be as high as 15% to 18%. About 75,000 pregnant women and 500,000 fetuses die from complications of preeclampsia each year [3 ], And the risk of future cardiovascular disease in patients with preeclampsia and their offspring are increased [4]. How to reduce the incidence of preeclampsia, the effective treatment of preeclampsia and its complications, is the majority of obstetrics and gynecology doctors today to study the goal. However, the mechanism of preeclampsia is still not completely understood at present, and nitric oxide (NO) / cyclic guanosinc monophosphate (cGMP) channels are considered as affecting